Menu Search
Equities

Ucb SA

UCB:BRU

Ucb SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)184.40
  • Today's Change2.90 / 1.60%
  • Shares traded278.90k
  • 1 Year change+174.49%
  • Beta0.6169
Data delayed at least 15 minutes, as of Nov 08 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy1
Outperform13
Hold6
Sell0
Strong Sell0

Share price forecast in EUR

The 18 analysts offering 12 month price targets for UCB SA have a median target of 174.00, with a high estimate of 250.00 and a low estimate of 105.00. The median estimate represents a -5.64% decrease from the last price of 184.40.
High35.6%250.00
Med-5.6%174.00
Low-43.1%105.00

Dividends in EUR

In 2023, Ucb SA reported a dividend of 0.95 EUR, which represents a 2.26% increase over last year. The 15 analysts covering the company expect dividends of 1.42 EUR for the upcoming fiscal year, an increase of 48.84%.
Div growth (TTM)2.26%
More ▼

Earnings history & estimates in EUR

UCB SA reported annual 2023 earnings of 4.20 per share on Feb 28, 2024.
Average growth rate-3.10%
More ▼

Revenue history & estimates in EUR

UCB SA had revenues for the full year 2023 of 5.25bn. This was 4.80% below the prior year's results.
Average growth rate+1.89%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.